File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: A new prognostic classification scheme with treatment guidelines for Asian patients with hepatocellular carcinoma (HCC): the Hong Kong Combined Liver Cancer (HKCLC) classification

TitleA new prognostic classification scheme with treatment guidelines for Asian patients with hepatocellular carcinoma (HCC): the Hong Kong Combined Liver Cancer (HKCLC) classification
Authors
Issue Date2011
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
The 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 4-8 June 2011. In Journal of Clinical Oncology, 2011, v. 29 n. 15 suppl., abstract no. 4067 How to Cite?
AbstractBACKGROUND: HCC patients in Asia mostly have different etiologies and have different treatment algorithm when compared with their Western counterparts. Despite the wide use in Western countries, the Barcelona Clinic Liver Cancer (BCLC) staging may not fit in the management of Asian patients. We aim to develop a new prognostic classification scheme with treatment guidelines for Asian HCC patients. METHODS: HCC patients treated at the Department of Surgery, Queen Mary Hospital between 1995 and 2008 were included. The scheme was developed by both statistical methodology and clinical judgment. Four established prognostic factors, namely ECOG PS, Child-Pugh grade, tumor status and presence of extrahepatic venous invasion/metastasis, were selected in building the scheme. A scoring system which assigns 'points' to each category of these 4 factors was developed using Cox regression on overall survival. The points and combined scores were referred to stratify patients to different staging with specific treatment recommendations. RESULTS: 3,617 patients were identified. The scheme stratifies patients to stages I to V with distinct overall survival outcomes. Selected patients had benefited from more aggressive treatments than what were recommended in BCLC. In patients who were classified as stage B in BCLC but I/II in HKCLC, the survival benefit of radical curative therapies over TACE was substantial (5-year survival probability: 0.479 vs 0.175; P<0.0001 by log-rank test). Similarly, in patients who were classified as stage C in BCLC but I/II in HKCLC, the survival benefit of radical curative therapies over systemic therapy was even more pronounced (5-year survival probability: 0.484 vs 0; P<0.0001 by log-rank test). Furthermore, in patients who were classified as stage C in BCLC but III in HKCLC, the survival benefit of TACE over systemic therapy was also significant (3-year survival probability: 0.087 vs 0.011; P<0.0001 by log-rank test). CONCLUSIONS: The HKCLC scheme may be able to identify patients suitable for treatments more aggressive than BCLC’s recommendations and thus yield a better survival outcome.
DescriptionThis journal suppl. entitled: ASCO Annual Meeting
Persistent Identifierhttp://hdl.handle.net/10722/137889
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorTang, YFen_US
dc.contributor.authorYao, Ten_US
dc.contributor.authorYau, CCen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorPoon, RTPen_US
dc.date.accessioned2011-08-26T14:36:27Z-
dc.date.available2011-08-26T14:36:27Z-
dc.date.issued2011en_US
dc.identifier.citationThe 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 4-8 June 2011. In Journal of Clinical Oncology, 2011, v. 29 n. 15 suppl., abstract no. 4067en_US
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/137889-
dc.descriptionThis journal suppl. entitled: ASCO Annual Meeting-
dc.description.abstractBACKGROUND: HCC patients in Asia mostly have different etiologies and have different treatment algorithm when compared with their Western counterparts. Despite the wide use in Western countries, the Barcelona Clinic Liver Cancer (BCLC) staging may not fit in the management of Asian patients. We aim to develop a new prognostic classification scheme with treatment guidelines for Asian HCC patients. METHODS: HCC patients treated at the Department of Surgery, Queen Mary Hospital between 1995 and 2008 were included. The scheme was developed by both statistical methodology and clinical judgment. Four established prognostic factors, namely ECOG PS, Child-Pugh grade, tumor status and presence of extrahepatic venous invasion/metastasis, were selected in building the scheme. A scoring system which assigns 'points' to each category of these 4 factors was developed using Cox regression on overall survival. The points and combined scores were referred to stratify patients to different staging with specific treatment recommendations. RESULTS: 3,617 patients were identified. The scheme stratifies patients to stages I to V with distinct overall survival outcomes. Selected patients had benefited from more aggressive treatments than what were recommended in BCLC. In patients who were classified as stage B in BCLC but I/II in HKCLC, the survival benefit of radical curative therapies over TACE was substantial (5-year survival probability: 0.479 vs 0.175; P<0.0001 by log-rank test). Similarly, in patients who were classified as stage C in BCLC but I/II in HKCLC, the survival benefit of radical curative therapies over systemic therapy was even more pronounced (5-year survival probability: 0.484 vs 0; P<0.0001 by log-rank test). Furthermore, in patients who were classified as stage C in BCLC but III in HKCLC, the survival benefit of TACE over systemic therapy was also significant (3-year survival probability: 0.087 vs 0.011; P<0.0001 by log-rank test). CONCLUSIONS: The HKCLC scheme may be able to identify patients suitable for treatments more aggressive than BCLC’s recommendations and thus yield a better survival outcome.-
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.titleA new prognostic classification scheme with treatment guidelines for Asian patients with hepatocellular carcinoma (HCC): the Hong Kong Combined Liver Cancer (HKCLC) classificationen_US
dc.typeConference_Paperen_US
dc.identifier.emailYao, T: tjyao@hku.hken_US
dc.identifier.emailYau, CC: tyaucc@hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hku.hk-
dc.identifier.authorityYao, T=rp00284en_US
dc.identifier.authorityYau, CC=rp01466en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.hkuros189728en_US
dc.identifier.volume29en_US
dc.identifier.issue15 suppl.en_US
dc.publisher.placeUnited States-
dc.description.otherThe 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 4-8 June 2011. In Journal of Clinical Oncology, 2011, v. 29 n. 15, suppl., abstract no. 4067-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats